OCCAM Immune, a Mount Sinai research organization, will sequence and map cells from samples collected in CRI's immunotherapy trials.

The companies aim to generate preclinical proof-of-concept data on SRB123 and quickly take it into clinical trials.

The funds will support the firm's lead programs, ABS-1230 for KCNT1-related epilepsy and ABS-0871 for TRPV4-positive Charcot-Marie-Tooth disease type 2C.

In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...